Recurrent hepatitis C post-transplantation: Where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop

Canadian Journal of Gastroenterology

Volumn 20, Issue 11, 2006, Pages 725-734

  Watt, Kymberly D S ^a   Burak, Kelly ^b   Deshênes, Marc ^c   Lilly, Les ^d   Marleau, Denis ^e   Marotta, Paul ^f   Mason, Andrew ^g   Peltekian, Kevork M ^a   Renner, Eberhard L ^h   Yoshida, Eric M ⁱ  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Management; Recurrent heaptitis C; Research; Risk factors; Transplantation

Indexed keywords

ALPHA INTERFERON; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERFERON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; STEROID; TACROLIMUS;

ADJUVANT THERAPY; ANEMIA; ANTIVIRAL ACTIVITY; CANADA; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DISEASE COURSE; DOSE KIDNEY FUNCTION RELATION; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; GRAFT FAILURE; GRAFT INFECTION; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RECURRENT VIRUS INFECTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS LOAD;

EID: 33845659868     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2006/238218     Document Type: Review

References (89)

1. Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: Is hepatitis C to blame? Liver Transpl 2003;9:1019-24.
2. Rosen H, Gretch DR, Oehlke M, et al. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998;65:1178-82.
3. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815-20.
4. Weinstein JS, Poterucha JJ, Zein N, Wiesner RH, Persing DH, Rakela J. Epidemiology and natural history of hepatitis C infections in liver transplant recipients. J Hepatol 1995;22(Suppl 1):154-9.
5. Testa G, Crippin JS, Netto GJ, et al. Liver transplantation for hepatitis C: Recurrence and disease progression in 300 patients. Liver Transpl 2000;6:553-61.
6. Sheiner P. Hepatitis C after liver transplantation. Semin Liver Dis 2000;20:201-9.
7. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol 2001;35:666-78.
8. Sanchez-Fueyos A, Restrepo JC, Quinto L, et al. Impact of the recurrence of hepatitis C infection after liver transplantation on the long term viability of the graft. Transplantation 2002;73:56-63.
9. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002;8(Suppl 1):S14-S8.
10. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-30.
11. Ghobrial RM, Farmer DG, Baquerizo A, et al. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression and causes of retransplantation during an eight year single center experience. Ann Surg 1999;6:824-33.
12. Casavilla FA, Rakela J, Kapur S, et al. Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg 1998;4:448-54.
13. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-96.
14. Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV- recipients. Transplantation 2004;77:1834-42.
15. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-84.
16. Prieto M, Berenguet M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999;29:250-6.
17. Rosen H, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998;66:1612-6.
18. Ghobrial RM, Steadman R, Gornbein J, et al. A ten year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-94.
19. Ghobrial RM, Gornbein J, Steadman R, et al. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg 2002;236:315-23.
20. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999;29:365-70.
21. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004;77:226-31.
22. Canadian Organ Replacement Register/Canadian Institute for Health Information, 2002.
23. Baron PW, Sindram D, Higdon D, et al. Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation. Liver Transpl 2000;6:407-12.
24. Watt KD, Lyden ER, Gulizia JM, McCashland TM. Recurrent hepatitis C post transplant: Early preservation injury may predict poor outcome. Liver Transpl 2006;12:134-9.
25. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003;9:1028-35.
26. Bozorgzadeh A, Jam A, Ryan C, et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. Transplantation 2004;77:1066-70.
27. Shiffman ML, Stravitz RT, Contos MJ, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004;10:1248-55.
28. Russo MW, Galanko J, Beavers K, Fried MW, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004;10:340-6.
29. Girgrah N, Lilly L, Chen D, et al. Recurrence of hepatitis C following living donor vs deceased donor liver transplantation. Am J Transplant 2005;5:1450A. (Abst)
30. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996;110:167-77.
31. Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999;21:253-61.
32. Papatheodoridis GV, Barton SG, Andrew D, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: The role of different immunosuppressive regimens. Gut 1999;45:427-34.
33. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-7.
34. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32:1125-30.
35. Filipponi F, Callea F, Salizzoni M, et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004;78:1488-95
36. Langrehr JM, Neumann UP, Lang M, et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc 2002;34:1565-6.
37. Kato T, Yoshida H, Sadfar K, et al. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: A preliminary report from a prospective randomized study. Transplant Proc 2005;37:1217-9.
38. Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporine a is mediated by blockade of cyclophilins. Gastroenterology 2005;129:1031-41.
39. Kakumu S, Takayanagi M, Iwata K, et al. Cyclosporine therapy affects aminotransferase activity but not hepatitis C virus RNA levels in chronic hepatitis C. J Gastroenterol Hepatol 1997;12:62-6.
40. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporine A in the treatment of chronic hepatitis C: Controlled trial. J Gastroenterol 2003;38:567-72.
41. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial. Liver Transpl 2004;10:1258-62.
42. Levy G, Villamil F, Samuel D, et al; LIS2T Study Group. Results of LIS2T, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation. Transplantation 2004;77:1632-8.
43. Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation of hepatitis C. Transplantation 1997;64:721-26.
44. Chopra K, Demetris AJ, Blakolmer K, et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003;76:1487-91.
45. Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: Results of the NIDDK liver transplantation database. Liver Transpl 2004;10:1120-30.
46. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-9.
47. Razonable RR, Burak KW, van Cruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Inf Dis 2002;35:974-81.
48. Humar A, Kumar D, Raboud J, et al. Interactions between cytomegalovirus, human herpesvirus-6 and the recurrence of hepatitis C after liver transplantation. Am J Transpl 2002;2:461-6.
49. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004;10:1240-7.
50. Teixeira R, Pastacladi S, Davies S, et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000;70:1454-8.
51. Singh N, Husain S, Carrigan DR, et al. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transpl 2002;16:92-6.
52. Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003;9:S90-4.
53. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-62.
54. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-5.
55. Wiesner RH, Sorrell M, Villamil F; International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1-S9.
56. Chalasani N, Manzarbeitia C, Ferenci P, et al; Pegasys Transplant Study Group. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005;41:289-98.
57. Mukherjee S, Rogge J, Weaver L, Schafer D. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transpl Proc 2003;35:3042-4.
58. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004;40:669-74.
59. Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alfa 2b and ribavirin: An open-label series. Transplantation 2004;77:190-4.
60. Ross AS, Bhan AK, Pascual M, Thiim M, Benedict Cosimi A, Chung RT. Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004;18:166-73.
61. Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004;78:1303-7.
62. Toniutto P, Fabris C, Fumo E, et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005;20:577-82.
63. Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005;19:359-65.
64. Shergill AK, Khalili M, Straley S, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005;5:118-24.
65. Bizollon T, Adham M, Pradat P, et al. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent post transplantation hepatitis C. Transplantation 2005;79:325-9.
66. Beckebaum S, Cicinnati VR, Zhang X, et al. Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: Preliminary results of an open prospective study. Transplant Proc 2004;36:1489-91.
67. McHutchison JG, Manns M, Patel K, et al; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
68. Stravitz RT, Chung H, Sterling RK, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005;100:1415-9.
69. Afdhal NH, Dieterich DT, Pockros PJ, et al; Proactive Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11.
70. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003;98:2491-9.
71. Younossi ZM, Ong JP, Collantes R, et al. Darbepoetin-alfa for ribavirin induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin: A preliminary analysis. Gastroenterology 2004;126;A666. (Abst)
72. Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995;42:907-12.
73. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002;36:3-10.
74. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: An update. Am J Kidney Dis 2003;42:631-57.
75. Kamar N, Rostaing L, Selves J, et al. Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005;5:1704-12.
76. Morales JM. Hepatitis C virus infection and renal disease after renal transplantation. Transplant Proc 2004;36:760-2.
77. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999;29:257-63.
78. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004;78:745-50.
79. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Meta-analysis: Interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003;18:1071-81.
80. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005;20:991-3.
81. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase of hepatocellular carcinoma in the United Status: An update. Ann Intern Med 2003;139:817.
82. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463.
83. Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol 2000;14:575-80.
84. Figueras J, Ibanez L, Ramos E, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: Results of a multicenter study. Liver Transpl 2001;7:877-83.
85. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
86. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
87. Vivarelli M, Cucchetti A, Piscaglia F, et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: Key role of immunosuppression. Liver Transpl 2005;11:497-503.
88. Law BK. Rapamycin: An anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005;56:47-60.
89. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004;10:1301-11.